TaiMed Biologics Inc. (TPEX:4147)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
51.40
+0.20 (0.39%)
At close: Feb 26, 2026
-48.24%
Market Cap 14.04B
Revenue (ttm) 607.22M
Net Income (ttm) -219.71M
Shares Out 273.20M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,428,752
Average Volume 940,067
Open 52.30
Previous Close 51.20
Day's Range 50.90 - 53.10
52-Week Range 50.90 - 101.00
Beta -0.09
RSI 23.69
Earnings Date Mar 25, 2026

About TaiMed Biologics

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antib... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4147
Full Company Profile

Financial Performance

In 2024, TaiMed Biologics's revenue was 610.16 million, an increase of 24.07% compared to the previous year's 491.78 million. Losses were -201.83 million, 3.60% more than in 2023.

Financial Statements

News

There is no news available yet.